



**LUMOS**  
DIAGNOSTICS

## ASX ANNOUNCEMENT

### Lumos Diagnostics Annual General Meeting Chair's Address

**MELBOURNE, Australia (14 November 2024)** – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid point-of-care (POC) diagnostic technologies, today releases the Chair’s Address for the 2024 Annual General Meeting as follows:

Welcome to the Lumos Diagnostics 2024 Annual General Meeting. My name is Sam Lanyon, and I am the Non-executive Chair of the Company.

Reflecting on the past year, I am pleased to address you on behalf of the Board. Alongside my fellow members, I am encouraged by the company's progress under the leadership of our CEO and Managing Director, Doug Ward, and his team. Over the last two years, they have shown strong commitment in building a solid foundation for Lumos' growth. We are now seeing the results of these efforts, positioning us for a promising future.

During this period, Lumos has made significant progress, securing regulatory clearances for our flagship diagnostic products, FebriDx and ViraDx, launching them commercially, and achieving initial sales. We have also successfully secured funding to support our goals. Importantly, our financial and operational position has been strengthened further through a key intellectual property and development agreement with Hologic, a global leader in women’s health solutions.

In particular, I want to highlight two major product clearances we received in the United States - for FebriDx<sup>®</sup> and ViraDx<sup>™</sup>. FebriDx<sup>®</sup> is our innovative rapid point-of-care diagnostic test, providing healthcare professionals with the ability to differentiate bacterial from non-bacterial infections quickly and reliably, addressing a pressing healthcare need in infection management. ViraDx<sup>™</sup>, on the other hand, is our rapid test for COVID-19, Flu A, and Flu B, which enables the timely identification of viral infections, essential for patient care during flu season. Achieving these clearances from the FDA demonstrates our team’s collective capability and expertise across research, development, regulatory compliance, and quality assurance.

Building a strong market presence for these products, especially in the United States, has been essential. Our team has ramped up production and established distribution channels, even with the challenges of entering the U.S. 2023/24 flu season later than we would have liked. This progress demonstrates our

For personal use only

operational flexibility and commitment to making essential diagnostic tools widely accessible in the healthcare market.

Our partnership with Hologic is another cornerstone of our growth trajectory. Since beginning in FY23, this collaboration has expanded, recently resulting in Intellectual Property and Development Agreements to support Hologic's next-generation Fetal Fibronectin (fFN) pre-term birth test. This partnership underscores our joint commitment to advancing women's health diagnostics and our ability to meet high industry standards. Lumos' financial position was bolstered by a US\$10.0 million IP payment from Hologic, with an additional US\$0.7 million received for milestone achievements so far and another US\$4.0 million expected as we advance the fFN product development.

As Doug Ward joined the Board this year, his role has been instrumental in aligning strategic direction and operational focus, alongside our valued Board members Larry, Catherine, and Bronwyn. I look forward to his continued contributions in this dual role, as he leads Lumos through its next phase of growth. Shortly, in his CEO address, Doug will discuss operational progress and provide additional insights on our roadmap for the coming year and beyond.

We also want to acknowledge the support of you, our shareholders. Last month, we successfully completed a A\$10.0 million capital raise. This funding will help us conduct a clinical trial to expand FebriDx to a CLIA-waived label in the US, broadening our market reach substantially, as well as support new product development and our working capital needs. I extend gratitude to the participating shareholders, including new supporter Tenmile and long-time investor Ryder Capital.

Looking ahead, I am confident in the solid foundations we have established. These not only provide financial stability, but a platform to continue developing innovative products, and new partnership opportunities in specialized healthcare segments. We are particularly excited to commence exploring new market opportunities in rapid, point-of-care tests in the women's health market. With these foundations, my belief is that the broader market will begin to recognise the value of this business and its bright future, which in turn will drive shareholder value.

In conclusion, I extend my sincere gratitude to the Lumos team for their hard work and expertise, to my fellow Board members for their insights, and to our shareholders for their support in our mission. Thank you, and I look forward to the journey ahead.

**-Ends-**

***This announcement is authorised for release by the Lumos Disclosure Committee***

### **About Lumos Diagnostics**

*Lumos Diagnostics specialises in rapid and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader*

platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com).

### **Forward-Looking Statements**

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

### **Media Contacts:**

Haley Chartres – Australia  
H^CK Director  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 (0) 423 139 163

### **Investor Contact:**

Jane Lowe  
Managing Director, IR Department  
[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)  
+61 411 117 774

### **Company Registered Office:**

Lumos Diagnostics Holdings Ltd  
Level 4, 100 Albert Rd  
South Melbourne, VIC 3205, Australia  
+61 3 9087 1598

For personal use only